Successful treatment of congenital acute myeloid leukemia (AML-M6) in a premature infant.
Successful treatment of congenital acute myeloid leukemia (AML-M6) in a premature infant.
复制标题
成功治疗早产儿先天性急性髓系白血病（AML-M6）。
DOI：
10.1097/mph.0b013e3181b38b6c
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
M. V. D. van den Heuvel
中科院分区：
文献类型：
--
作者：
Joyce C A van Dongen;M. Dalinghaus;A. Kroon;A. D. de Vries;M. V. D. van den Heuvel
先天性急性髓系白血病(AML)，尤其是AML-M6是一种少见的疾病，预后差。此外，没有关于早产儿先天性AML-M6的治疗结果的报道。我们报告了第一例先天性急性髓细胞白血病-M6的治疗病例，早产儿接受了完整的急性髓细胞白血病方案。她出现蓝莓松饼斑点，贫血，白细胞计数高，以及严重的心肺窘迫。外周血涂片显示AML-M6细胞。在出生后连续小剂量阿糖胞苷治疗和2个月大时按MRC-12方案全剂量治疗AML后，她现在持续完全缓解4年。
Congenital acute myeloid leukemia (AML), and especially AML-M6 is a rare disease with a poor prognosis. Moreover, reports of treatment outcome of congenital AML-M6 in premature infants are not available. We report the first treated case of congenital AML-M6 in a premature girl, who received a full AML protocol. She presented with blueberry-muffin spots, anemia, high white blood cell count, and serious cardiopulmonary distress. Peripheral blood smears showed AML-M6 blasts. After treatment with a sequential low-dose cytarabine after birth and full-dose AML treatment according to the MRC-12 protocol at the age of 2 months, she now is in continuous complete remission for 4 years.